UMB Bank n.a. Increases Stake in Bristol-Myers Squibb (NYSE:BMY)

UMB Bank n.a. increased its position in shares of Bristol-Myers Squibb (NYSE:BMY - Free Report) by 178.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 205,457 shares of the biopharmaceutical company's stock after purchasing an additional 131,595 shares during the quarter. UMB Bank n.a.'s holdings in Bristol-Myers Squibb were worth $11,621,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of BMY. Seven Eight Capital LP purchased a new stake in Bristol-Myers Squibb in the 2nd quarter worth about $392,000. Benjamin F. Edwards & Company Inc. increased its stake in shares of Bristol-Myers Squibb by 6.0% in the second quarter. Benjamin F. Edwards & Company Inc. now owns 94,911 shares of the biopharmaceutical company's stock worth $3,941,000 after purchasing an additional 5,382 shares in the last quarter. Bridges Investment Management Inc. raised its position in shares of Bristol-Myers Squibb by 15.6% in the second quarter. Bridges Investment Management Inc. now owns 14,600 shares of the biopharmaceutical company's stock valued at $606,000 after purchasing an additional 1,971 shares during the period. AE Wealth Management LLC lifted its stake in shares of Bristol-Myers Squibb by 17.2% during the 2nd quarter. AE Wealth Management LLC now owns 108,803 shares of the biopharmaceutical company's stock valued at $4,519,000 after buying an additional 15,934 shares in the last quarter. Finally, Ameritas Investment Partners Inc. boosted its holdings in Bristol-Myers Squibb by 0.6% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 55,336 shares of the biopharmaceutical company's stock worth $2,298,000 after buying an additional 338 shares during the period. 76.41% of the stock is owned by institutional investors.

Insider Transactions at Bristol-Myers Squibb

In related news, EVP Samit Hirawat bought 1,830 shares of the firm's stock in a transaction on Friday, November 1st. The stock was acquired at an average cost of $54.67 per share, for a total transaction of $100,046.10. Following the purchase, the executive vice president now owns 62,109 shares in the company, valued at approximately $3,395,499.03. This represents a 3.04 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Phil M. Holzer sold 700 shares of the company's stock in a transaction on Monday, November 4th. The shares were sold at an average price of $55.62, for a total value of $38,934.00. Following the sale, the senior vice president now owns 11,760 shares of the company's stock, valued at approximately $654,091.20. This trade represents a 5.62 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 0.09% of the company's stock.

Bristol-Myers Squibb Trading Down 0.0 %

BMY stock traded down $0.03 during trading on Monday, reaching $56.35. The company had a trading volume of 10,909,530 shares, compared to its average volume of 10,195,547. The company has a debt-to-equity ratio of 2.83, a current ratio of 1.24 and a quick ratio of 1.09. Bristol-Myers Squibb has a 52 week low of $39.35 and a 52 week high of $61.08. The business has a 50 day moving average of $57.53 and a 200 day moving average of $52.09. The company has a market cap of $114.30 billion, a P/E ratio of -15.70, a PEG ratio of 1.95 and a beta of 0.45.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last released its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported $1.80 earnings per share for the quarter, beating the consensus estimate of $1.49 by $0.31. The company had revenue of $11.89 billion for the quarter, compared to analyst estimates of $11.26 billion. Bristol-Myers Squibb had a positive return on equity of 11.94% and a negative net margin of 15.30%. The firm's revenue was up 8.4% on a year-over-year basis. During the same period in the previous year, the company posted $2.00 earnings per share. As a group, sell-side analysts forecast that Bristol-Myers Squibb will post 0.93 earnings per share for the current fiscal year.

Bristol-Myers Squibb Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, February 3rd. Shareholders of record on Friday, January 3rd will be issued a $0.62 dividend. This is a positive change from Bristol-Myers Squibb's previous quarterly dividend of $0.60. The ex-dividend date of this dividend is Friday, January 3rd. This represents a $2.48 dividend on an annualized basis and a dividend yield of 4.40%. Bristol-Myers Squibb's dividend payout ratio (DPR) is presently -69.08%.

Wall Street Analysts Forecast Growth

BMY has been the subject of several recent research reports. Leerink Partnrs upgraded Bristol-Myers Squibb from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, November 12th. Jefferies Financial Group raised Bristol-Myers Squibb from a "hold" rating to a "buy" rating and lifted their target price for the company from $63.00 to $70.00 in a report on Monday, December 16th. TD Cowen raised their price objective on shares of Bristol-Myers Squibb from $53.00 to $59.00 and gave the company a "hold" rating in a research report on Monday, October 7th. Morgan Stanley upped their target price on shares of Bristol-Myers Squibb from $36.00 to $39.00 and gave the stock an "underweight" rating in a report on Tuesday, November 12th. Finally, Leerink Partners upgraded shares of Bristol-Myers Squibb from a "market perform" rating to an "outperform" rating and boosted their price target for the company from $55.00 to $73.00 in a research report on Tuesday, November 12th. Two research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, four have issued a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Hold" and a consensus target price of $56.27.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.